(Q37828056)

23 August 2017

1 reference

title

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication (English)

1 reference

23 August 2017

main subject

anti-retroviral agent

0 references

author name string

Frank Maldarelli

series ordinal

1

1 reference

23 August 2017

publication date

1 January 2011

1 reference

Current Opinion in HIV and AIDS

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

49-56

1 reference

Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker

23 August 2017

cites work

1 reference

12 December 2020

Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia

1 reference

12 December 2020

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

1 reference

12 December 2020

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

1 reference

12 December 2020

Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles

1 reference

12 December 2020

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

12 December 2020

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

1 reference

12 December 2020

Role of macrophages in HIV infection and persistence

1 reference

12 December 2020

Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients

1 reference

12 December 2020

Human immunodeficiency virus type 1 assembly, release, and maturation.

1 reference

12 December 2020

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

12 December 2020

Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase

1 reference

12 December 2020

Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors

1 reference

12 December 2020

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention

1 reference

12 December 2020

Raltegravir: the first HIV type 1 integrase inhibitor

1 reference

12 December 2020

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro

1 reference

12 December 2020

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen

1 reference

12 December 2020

Identification of two mutually exclusive groups after long-term monitoring of HIV DNA 2-LTR circle copy number in patients on HAART.

1 reference

12 December 2020

A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

1 reference

12 December 2020

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

1 reference

12 December 2020

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

1 reference

12 December 2020

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro

1 reference

12 December 2020

Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.

1 reference

12 December 2020

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

1 reference

12 December 2020

In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.

1 reference

12 December 2020

Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection.

1 reference

12 December 2020

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

12 December 2020

Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy

1 reference

12 December 2020

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle

1 reference

12 December 2020

Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus

1 reference

12 December 2020

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

12 December 2020

A long-term latent reservoir for HIV-1: discovery and clinical implications

1 reference

12 December 2020

HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir

1 reference

12 December 2020

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

1 reference

12 December 2020

HIV rebounds from latently infected cells, rather than from continuing low-level replication

1 reference

12 December 2020

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

12 December 2020

Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology

1 reference

12 December 2020

Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition

1 reference

12 December 2020

Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals

1 reference

12 December 2020

Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells

1 reference

12 December 2020

Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication

1 reference

12 December 2020

Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1.

1 reference

12 December 2020

2-LTR circular viral DNA as a marker for human immunodeficiency virus type 1 infection in vivo

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions

1 reference

12 December 2020

Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.

1 reference

12 December 2020

Quantitation of human immunodeficiency virus type 1 infection kinetics

1 reference

12 December 2020

Effect of protease inhibitors on HIV-1 maturation and infectivity

1 reference

12 December 2020

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

12 December 2020

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

1 reference

12 December 2020

A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children

1 reference

12 December 2020

HIV-1 TAR RNA: the target of molecular interactions between the virus and its host

1 reference

12 December 2020

Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles

1 reference

12 December 2020

A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients

1 reference

12 December 2020

Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

1 reference

12 December 2020

Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretro

1 reference

12 December 2020

Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5.

1 reference

12 December 2020

Emerging pharmacology: inhibitors of human immunodeficiency virus integration

1 reference

12 December 2020

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

1 reference

12 December 2020

10.1097/COH.0B013E32834134EA

Identifiers

DOI

1 reference

23 August 2017

1 reference